Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study 16th Winter Workshop of the Canadian-Rheumatology-Association Genovese, M., Brown, J. P., McKay, J., Nasonov, E., Mysler, E., da Silva, N., Alecock, E., Gomez-Reino, J. J RHEUMATOL PUBL CO. 2008: 1187–87
View details for Web of Science ID 000256503900091